Skip to main content
Top
Published in: BMC Infectious Diseases 1/2017

Open Access 01-12-2017 | Research article

Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study

Authors: Mahlet Semu, Teferi Gedif Fenta, Girmay Medhin, Dawit Assefa

Published in: BMC Infectious Diseases | Issue 1/2017

Login to get access

Abstract

Background

Human Immunodeficiency Virus (HIV) pandemic has exacerbated tuberculosis disease especially in Sub-Saharan African countries. The World Health Organization (WHO) and Joint United Nations Program on HIV/AIDS (UNAIDS) have recommended Isoniazid Preventive Therapy (IPT) for HIV infected patients to reduce the burden of tuberculosis (TB). Ethiopia has been implementing IPT since 2007. However, effectiveness of IPT in averting occurrence of active tuberculosis among HIV infected patients has not been assessed.

Methods

Retrospective cohort study was employed using secondary data from public health institutions of Addis Ababa. Descriptive statistics and Generalized Linear Model based on Poisson regression was used for data analysis.

Results

From 2524 HIV infected patients who were followed for 4106 Person-Years, a total of 277 incident Tuberculosis (TB) cases occurred. TB Incidence Rate was 0.21/100 Person-Year, 0.86/100 Person-Year & 7.18/100 Person-Year among IPT completed, in-completed and non-exposed patients, respectively. The adjusted Incidence Rate Ratio (aIRR) among IPT completed vs. non-exposed patients was 0.037 (95% CI, 0.016-0.072). Gender, residence area, employment status, baseline WHO stage of the disease (AIDS) and level of CD4 counts were identified as risk factors for TB incidence. The aIRR among patients who took Highly Active Anti- Retroviral Therapy (HAART) with IPT compared to those who took HAART alone was 0.063 (95% CI 0.035-0.104). IPT significantly reduced occurrence of active TB for 3 years.

Conclusions

IPT significantly reduced tuberculosis incidence by 96.3% compared to IPT non-exposed patients. Moreover concomitant use of HAART with IPT has shown a significant reduction in tuberculosis incidence by 93.7% than the use of HAART alone. Since IPT significantly protected occurrence of active TB for 3 years, its implementation should be further strengthened in the country.
Literature
1.
go back to reference Friedland G, Churchyard GJ, Nardell E. Tuberculosis and HIV coinfection: current state of knowledge and research priorities. JID. 2007;196 Suppl 1:S1.CrossRefPubMed Friedland G, Churchyard GJ, Nardell E. Tuberculosis and HIV coinfection: current state of knowledge and research priorities. JID. 2007;196 Suppl 1:S1.CrossRefPubMed
4.
go back to reference Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897–908.CrossRefPubMed Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22:1897–908.CrossRefPubMed
6.
go back to reference FMOH. Health Sector Development Program IV, 2010/11 – 2014/15. Federal Democratic Republic of Ethiopia, Ministry of Health. Version 19. Addis Ababa, Ethiopia. FMOH. Health Sector Development Program IV, 2010/11 – 2014/15. Federal Democratic Republic of Ethiopia, Ministry of Health. Version 19. Addis Ababa, Ethiopia.
10.
go back to reference FMOH: Implementation Guideline for TB/HIV Collaborative Activities in Ethiopia. Federal Ministry of Health: Addis Ababa, Ethiopia; 2008/09. FMOH: Implementation Guideline for TB/HIV Collaborative Activities in Ethiopia. Federal Ministry of Health: Addis Ababa, Ethiopia; 2008/09.
11.
go back to reference Belew D. Process evaluation of isoniazid prophylaxis program for HIV positive patients in the ENARP site. Master’s thesis. Addis Ababa: Department of Community Health, Addis Ababa University; 2004. Belew D. Process evaluation of isoniazid prophylaxis program for HIV positive patients in the ENARP site. Master’s thesis. Addis Ababa: Department of Community Health, Addis Ababa University; 2004.
12.
go back to reference Vieira de Souza CT, Hökerberg YHM, Pacheco SJB, et al. Effectiveness and safety of isoniazid chemoprophylaxis for HIV-1 infected patients from Rio de Janeiro. Mem Inst Oswaldo Cruz. 2009;104(3):462–7.CrossRef Vieira de Souza CT, Hökerberg YHM, Pacheco SJB, et al. Effectiveness and safety of isoniazid chemoprophylaxis for HIV-1 infected patients from Rio de Janeiro. Mem Inst Oswaldo Cruz. 2009;104(3):462–7.CrossRef
13.
go back to reference Teferi T, Iyaloo J, Kalibbala M, Makai R, Hango JN, Nkongolo OT, et al. Effect of primary isoniazid preventive therapy on tuberculosis incidence rate among HIV-infected adults enrolled in HIV care in northern Namibia: a retrospective cohort study. In: AIDS 2012 - XIX International AIDS Conference, 2012: Abstract WEPE066. 22-27 July 2012. Washington, D.C. http://pag.aids2012.org/Abstracts.aspx?AID=7130. (Accessed 25 Oct 2015). Teferi T, Iyaloo J, Kalibbala M, Makai R, Hango JN, Nkongolo OT, et al. Effect of primary isoniazid preventive therapy on tuberculosis incidence rate among HIV-infected adults enrolled in HIV care in northern Namibia: a retrospective cohort study. In: AIDS 2012 - XIX International AIDS Conference, 2012: Abstract WEPE066. 22-27 July 2012. Washington, D.C. http://​pag.​aids2012.​org/​Abstracts.​aspx?​AID=​7130. (Accessed 25 Oct 2015).
14.
go back to reference Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons (Cochrane Review). The Cochrane Library, Issue 3. Chichester (UK): Wiley; 2004. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons (Cochrane Review). The Cochrane Library, Issue 3. Chichester (UK): Wiley; 2004.
15.
go back to reference Fennera L, Forstera M, Boulleb A, et al. Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. Int J Tuberc Lung Dis. 2011;15(5):620–7.CrossRef Fennera L, Forstera M, Boulleb A, et al. Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. Int J Tuberc Lung Dis. 2011;15(5):620–7.CrossRef
16.
go back to reference Grant AD, Charalambous S, Fielding KL, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA. 2005;293(22):2719–25.CrossRefPubMed Grant AD, Charalambous S, Fielding KL, et al. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA. 2005;293(22):2719–25.CrossRefPubMed
17.
go back to reference Khawcharoenporn T, Apisarnthanarak A, Manosuthi W, et al. Isoniazid preventive therapy and 4-year incidence of pulmonary tuberculosis among HIV infected Thai patients. Int J Tuberc Lung Dis. 2012;16(3):336–41. doi:10.5588/ijtld.11.0402.CrossRefPubMed Khawcharoenporn T, Apisarnthanarak A, Manosuthi W, et al. Isoniazid preventive therapy and 4-year incidence of pulmonary tuberculosis among HIV infected Thai patients. Int J Tuberc Lung Dis. 2012;16(3):336–41. doi:10.​5588/​ijtld.​11.​0402.CrossRefPubMed
18.
go back to reference World Health Organization (WHO). Report of a “lessons learnt” workshop on the six ProTEST pilot projects in Malawi, South Africa, and Zambia [WHO/HTM/TB/2004.336]. Geneva: WHO; 2004. World Health Organization (WHO). Report of a “lessons learnt” workshop on the six ProTEST pilot projects in Malawi, South Africa, and Zambia [WHO/HTM/TB/2004.336]. Geneva: WHO; 2004.
19.
go back to reference Getahun H, Gunneberg C, Granich R, et al. HIV infection associated tuberculosis: the epidemiology and the response. Clinical Infectious Diseases. 2010;50 suppl 3:S201–7. doi:10.1086/651492.CrossRefPubMed Getahun H, Gunneberg C, Granich R, et al. HIV infection associated tuberculosis: the epidemiology and the response. Clinical Infectious Diseases. 2010;50 suppl 3:S201–7. doi:10.​1086/​651492.CrossRefPubMed
20.
go back to reference Golub EJ, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis Risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23(5):631–6.CrossRefPubMedPubMedCentral Golub EJ, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis Risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23(5):631–6.CrossRefPubMedPubMedCentral
Metadata
Title
Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study
Authors
Mahlet Semu
Teferi Gedif Fenta
Girmay Medhin
Dawit Assefa
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2017
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-016-2109-7

Other articles of this Issue 1/2017

BMC Infectious Diseases 1/2017 Go to the issue